Holen Sie sich die Stockscreener-App
0.687
17.72%
-0.148
Handel nachbörslich:
.74
0.053
+7.71%
Schlusskurs vom Vortag:
$0.835
Offen:
$0.7311
24-Stunden-Volumen:
444.10K
Relative Volume:
8.69
Marktkapitalisierung:
$37.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.67M
KGV:
-0.1218
EPS:
-5.64
Netto-Cashflow:
$-20.41M
1W Leistung:
-39.20%
1M Leistung:
-32.65%
6M Leistung:
-65.65%
1J Leistung:
-39.20%
1-Tages-Spanne:
$0.65
$0.7451
1-Wochen-Bereich:
$0.65
$1.20
52-Wochen-Spanne:
$0.65
$2.625
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Firmenname
Eterna Therapeutics Inc
Sektor
Branche
Telefon
(212) 582-1199
Adresse
1035 CAMBRIDGE STREET, CAMBRIDGE
Vergleichen Sie ERNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ERNA | 0.687 | 37.59M | 0 | -21.67M | -20.41M | -5.64 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Eterna Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
ERNA Stock Hits 52-Week Low at $0.83 Amid Market Challenges - Investing.com India
Eterna Therapeutics regains Nasdaq compliance, focuses on cancer therapy - Investing.com
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - The Manila Times
Eterna Therapeutics Regains Nasdaq Compliance, Advances Cancer Treatment Pipeline | ERNA Stock News - StockTitan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com - MarketBeat
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock - Investing.com
Eterna Therapeutics shareholder Charles Cherington sells $6.54m in stock By Investing.com - Investing.com UK
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewswire
Eterna Therapeutics announces share issuance and executive agreements By Investing.com - Investing.com South Africa
Eterna Therapeutics announces share issuance and executive agreements - Investing.com India
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna, Factor announce license, collaboration agreement - Yahoo Finance
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - BioSpace
Eterna secures exclusive license for cell therapy tech - Investing.com India
Eterna secures exclusive license for cell therapy tech By Investing.com - Investing.com UK
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewswire
Eterna Therapeutics : Presentation (ZwKlOLVsGrYSwatS Zv 5rrVsGrYSwY0B EternaTherapeutics FactSheet October03%2C2024Final v1) - Marketscreener.com
Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest - Defense World
Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals - Investing.com
Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech - TipRanks
Eterna Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Eterna Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Eterna Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Eterna Therapeutics Inc. announced that it expects to receive $5.037748 million in funding - Marketscreener.com
Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Eterna Therapeutics (NASDAQ:ERNA) Shares Up 2.4% - Defense World
Eterna Therapeutics sets September 27 for annual meeting By Investing.com - Investing.com Australia
Eterna Therapeutics sets September 27 for annual meeting - Investing.com
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024 - MSN
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewswire
Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Receives New Coverage from Analysts at StockNews.com - Defense World
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics - Quantisnow
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared ... - Quantisnow
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index - Quantisnow
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing - Quantisnow
Brooklyn ImmunoTherapeutics Reports Inducement Grants - Quantisnow
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement - Quantisnow
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Finanzdaten der Eterna Therapeutics Inc-Aktie (ERNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):